Observing IBD patients with fatty liver disease
A Bidirectional, Multicenter Cohort Study of Inflammatory Bowel Disease (IBD) Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
This study looks at people with inflammatory bowel disease to see how common fatty liver disease is among them and how it affects their overall health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 337 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shanghai East Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06939569 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with inflammatory bowel disease (IBD) and examines the prevalence and impact of non-alcoholic fatty liver disease (NAFLD) among them. It aims to identify the similarities and differences between IBD patients with and without NAFLD, as well as to assess how the presence and severity of NAFLD may influence the clinical outcomes of IBD. The study will utilize a cohort of previously established IBD patients to gather relevant clinical data and insights.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with inflammatory bowel disease.
Not a fit: Patients with incomplete clinical data or severe comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the relationship between IBD and NAFLD, leading to improved management strategies for affected patients.
How similar studies have performed: There have been no relevant studies to date that specifically address the relationship between IBD and NAFLD, making this approach novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subjects aged over 18 years (including borderline values), of either sex. 2. Subjects consistented with the Chinese consensus on the diagnosis and treatment of IBD; 3. Subjects able to cooperate with follow-up, participate in this study and sign the informed consent. Exclusion Criteria: 1. Subjects with incomplete clinical data; 2. Subjects can not to cooperate with follow-up, and refuse to sign the informed consent; 3. Subjects can not to cooperate with the completion of relevant examinations; 4 Pregnant women; 5.Subjects with severe heart, lung, kidney and other organ diseases or cancer, and expected survival time less than 6 months.
Where this trial is running
Shanghai
- Shanghai East Hospital — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Lan Zhong, MD
- Email: lanzhong@tongji.edu.cn
- Phone: 8613162099450
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.